Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/10219
Title: Heterocyclyl linked A- ketoesters as novel antidiabetic agents: design synthesis and computational validation studies
Researcher: Ghosh, Prithwish
Guide(s): Verma, Raman K
Keywords: Diabetes
Chemistry
Upload Date: 31-Jul-2013
University: Punjabi University
Completed Date: 2012
Abstract: Type 2 diabetes mellitus (T2DM) has emerged as an epidemic in our country as well as globally. Cardiovascular complications have been known to alter the lifestyle and reduce the life expectancy of patients with type 2 diabetes. Renal failure, blindness, limb amputation, obesity etc. are other complications associated with T2DM. PPARs are crucial in regulation of energy homeostasis, with each of the three subtypes of PPAR receptors controlling particular aspects, hence are important therapeutic targets for the treatment of T2DM. Since the cloning of PPAR as an orphan receptor, various ligands and target genes have been identified. Indeed, PPAR agonists have emerged as a promising group of agents for treating type 2 diabetes and associated cardiovascular risk factors represented by the marketed 2,4-thiazolidenediones (TZDs). Natural and synthetic ligands for the three PPAR subtypes have been reported, mainly focusing on PPARand#947;. The identification of new ligands, added to improved knowledge of their specificity, will enlarge the panel drugs for therapeutic intervention in various energy homeostasis dysfunctions. In particular, PPARand#945; and PPARand#947; seem to be antagonizing partners in maintenance of lipid homeostasis. The PPARand#948;/and#946; isotype function has been the least documented thus far and would benefit from further development of pharmacological tools. However, its ubiquitous expression, particularly high during development, suggests that PPARand#948;/and#946; could be implicated in cell proliferation/differentiation or in more basic cellular functions such as cell membrane synthesis. On the basis of the relatively few compounds marketed until now, PPAR ligands have attracted much unfavorable attention because of their potential side effects. Ongoing pharmaceutical research is continuing to pursue PPAR ligands with enhanced therapeutic efficacy and better safety margins.
Pagination: 707p.
URI: http://hdl.handle.net/10603/10219
Appears in Departments:Department of Chemistry

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File85.26 kBAdobe PDFView/Open
02_certificate.pdf180.1 kBAdobe PDFView/Open
03_declaration.pdf101.06 kBAdobe PDFView/Open
04_dedication.pdf68.34 kBAdobe PDFView/Open
05_acknowledgements.pdf21.95 kBAdobe PDFView/Open
06_contents.pdf142.02 kBAdobe PDFView/Open
07_chapter 1.pdf1.51 MBAdobe PDFView/Open
08_chapter 2.pdf3.18 MBAdobe PDFView/Open
09_chapter 3.pdf5.4 MBAdobe PDFView/Open
10_chapter 4.pdf22.09 MBAdobe PDFView/Open
11_chapter 5.pdf658.15 kBAdobe PDFView/Open
12_references.pdf564.02 kBAdobe PDFView/Open
13_abstract.pdf122.2 kBAdobe PDFView/Open


Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.